Based on a review of the data regarding the use of ECF (epirubicin, cisplatin, and fluorouracil) and ECF modifications (epirubicin, oxaliplatin or cisplatin, and fluorouracil or capecitabine) as perioperative chemotherapy options for adenocarcinoma in medically fit patients. Based on the vote results, panel consensus supported making the following changes:
- Changed ECF (epirubicin, cisplatin and fluorouracil) from category 1 to category 3
- Changed ECF modifications (epirubicin, oxaliplatin or cisplatin, and fluorouracil or capecitabine) from category 2A to category 3 for all modifications.

Based on a review of the data in the noted clinical trial reference, the panel supported adding “fluorouracil and cisplatin (category 2B)” as preoperative chemotherapy (only for adenocarcinoma of the thoracic esophagus or EGJ).

Based on a review of the data, the panel supported moving the following first-line therapy options for metastatic or locally advanced cancer from the list of “Preferred Regimens” to the list of “Other Regimens”:
- ECF
- ECF modifications

Based on a review of the data and clinical experience, panel consensus supported removing the “Alternative Regimens for Consideration” section along with the following systemic therapy options for metastatic or locally advanced cancer:
- Mitomycin and irinotecan
- Mitomycin and fluorouracil